A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers. Academic Article uri icon

Overview

abstract

  • Purpose: Squamous cell lung cancers (SQCLC) account for 25% of all NSCLCs, yet the prognosis of these patients is poor and treatment options are limited. Amplified FGFR1 is one of the most common oncogenic events in SQCLCs, occurring in approximately 20% of cases. AZD4547 is a potent and selective FGFR1-3 inhibitor with antitumor activity in FGFR1-amplified SQCLC cell lines and patient-derived xenografts.Experimental Design: On the basis of these data, we performed a phase I study of AZD4547 in patients with previously treated stage IV FGFR1-amplified SQCLCs (NCT00979134). FGFR1 amplification (FGFR1:CEP8 ≥ 2) was determined by FISH. The primary endpoint was safety/tolerability. Secondary endpoints included antitumor activity, pharmacokinetics, pharmacodynamics, and molecular analyses.Results: Fifteen FGFR1-amplified patients were treated. The most common related adverse events (AE) were gastrointestinal and dermatologic. Grade ≥3-related AEs occurred in 3 patients (23%). Thirteen patients were evaluable for radiographic response assessment. The overall response rate was 8% (1 PR). Two of 15 patients (13.3%) were progression-free at 12 weeks, and the median overall survival was 4.9 months. Molecular tests, including next-generation sequencing, gene expression analysis, and FGFR1 immunohistochemistry, showed poor correlation between gene amplification and expression, potential genomic modifiers of efficacy, and heterogeneity in 8p11 amplicon.Conclusions: AZD4547 was tolerable at a dosage of 80 mg oral twice a day, with modest antitumor activity. Detailed molecular studies show that these tumors are heterogeneous, with a range of mutational covariates and stark differences in gene expression of the 8p11 amplicon that likely explain the modest efficacy of FGFR inhibition in this disease. Clin Cancer Res; 23(18); 5366-73. ©2017 AACR.

authors

  • Paik, Paul K.
  • Shen, Ronglai
  • Berger, Michael
  • Ferry, David
  • Soria, Jean-Charles
  • Mathewson, Alastair
  • Rooney, Claire
  • Smith, Neil R
  • Cullberg, Marie
  • Kilgour, Elaine
  • Landers, Donal
  • Frewer, Paul
  • Brooks, Nigel
  • André, Fabrice

publication date

  • June 14, 2017

Research

keywords

  • Antineoplastic Agents
  • Benzamides
  • Carcinoma, Squamous Cell
  • Lung Neoplasms
  • Piperazines
  • Pyrazoles

Identity

PubMed Central ID

  • PMC5600836

Scopus Document Identifier

  • 85029477795

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-17-0645

PubMed ID

  • 28615371

Additional Document Info

volume

  • 23

issue

  • 18